Early promising results in malaria vaccine trial in Mali

A small clinical trial conducted by an international team of researchers in Mali has found that a candidate malaria vaccine was safe and elicited strong immune responses in the 40 Malian adults who received it.

The trial was the first to test this vaccine candidate, which is designed to block the malaria parasite from entering human blood cells, in a malaria-endemic country. Based on these promising results, the research team is now conducting trials of this vaccine in 400 Malian children aged 1 to 6 years. Malaria is a leading killer in Africa and other developing countries, claiming more than 1 million lives each year, most of them children.

Lead investigator Mahamadou A. Thera M.D., MPH, and 16 other co-authors of the newly published study are based at the Malaria Research and Training Center at the University of Bamako, Mali. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, supported the trial and helps fund the Center. University of Maryland School of Medicine researcher Christopher Plowe, M.D., MPH, was the co-leader of the study.

The trial enrolled volunteers living in Bandiagara, a rural town in northeast Mali with a heavy burden of malaria. In this relatively dry region, almost no new infections occur during the driest month of the year, March, but people typically get up to 60 malaria-transmitting mosquito bites per month in August and September, when the rainy season peaks.

A total of 60 participants were assigned at random to receive either a full or half-dose of the candidate malaria vaccine or a licensed rabies vaccine, which served as a control. Each volunteer received three injections, spaced one month apart. Injections began in late December 2004, at the end of the malaria transmission season. As expected, all volunteers had significant levels of antibodies against malaria parasites detectable in their blood at the beginning of the trial, signaling that they had prior exposure to malaria parasites.

Those who received the candidate vaccine tolerated it very well and experienced a significant boost (up to a sixfold rise) in levels of vaccine-specific antibodies, while those who received the rabies vaccine had declining levels of antibodies as the rainy season receded.

Source: NIH/National Institute of Allergy and Infectious Diseases

Related stories:

Engineers create new technique for malaria diagnosis
Researchers from the Universities of Exeter and Coventry have developed the first new technique for diagnosing malaria able to challenge the rapid diagnostic tests (RDTs) currently used in the field.
Malaria vaccine trials begin using 'chimpanzee virus'
Trials are underway, funded by the Wellcome Trust, for a new vaccine to combat the most deadly form of malaria. For the first time ever, researchers will use a virus found in chimpanzees to boost the efficacy of the vaccine. The trials will take place at the University of Oxford's Jenner Institute, led by its Director, Professor Adrian Hill.
New malaria drug works in infants
Scientists say a new malaria vaccine being tested in Mozambique was successful in protecting infants less than 1 year old.
Gates: $258 million for malaria research
The Bill and Melinda Gates Foundation has given $258 million in malaria research grants.
The foundation says malaria kills an estimated 2,000 African children each day and takes the lives of more than 1 million people worldwide annually.
How the malaria parasite hijacks human red blood cells
A new study—done on a scale an order of magnitude greater than anything previously attempted in the field of malaria—has uncovered an arsenal of proteins produced by the malaria parasite that allows it to hijack and remodel human red blood cells, leaving the oxygen-carrying cells stiff and sticky. Those effects on the blood cells play a major role in the development of malaria, a disease responsible for millions of deaths every year, the researchers report in the July 11th issue of the journal Cell, a Cell Press publication.
Parasite vaccines within reach
Even though parasites are complex creatures, the mammalian immune response to them is surprisingly simple, leading University of California, Berkeley, researchers to predict that creating vaccines for parasitic diseases such as malaria may be more straightforward than initially thought.
Discovery to hasten new malaria treatments, vaccines for children
April 25 is World Malaria Day 2008 and despite the grim statistics out of Africa there’s cause for celebration. Florida State University biologists have discovered an autoimmune-like response in blood drawn from malaria-infected African children that helps to explain why existing DNA-based anti-malaria vaccines have repeatedly failed to protect them.
With annual deaths from malaria on the rise: Scientists ask 'where is all the money going?'
A new study in the April issue of the American Journal of Tropical Medicine and Hygiene, asks the question "With more than $220 million dollars dedicated to malaria treatment and prevention, why is the annual mortality rate from malaria on the rise?"

News discussion:

Medicine & Health news